Effects of BM-573, a Novel Thromboxane A2 Inhibitor, on Pulmonary Hemodynamics in Endotoxic Shock

Archives of Physiology and Biochemistry

Volumn 111, Issue 3, 2003, Pages 224-231

  Lambermont, B ^a,d   Ghuysen, A ^a   Dogne J M ^a   Kolh, P ^a   Tchana Sato, V ^a,c   Morimont, P ^a   Benoit, P ^a   Gerard P ^a   Masereel, B ^b   D'Orio, V ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c Aspirant FNRS ^*  (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antagonists; Endotoxins; Hemodynamics; Models; Pulmonary circulation; Septic shock; Swine; Thromboxane

Indexed keywords

BM 573; PLACEBO; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY COMPLIANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG STRUCTURE; EVOLUTION; FEMALE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; SEPTIC SHOCK; SWINE; TIME;

ANIMALS; ARACHIDONIC ACID; BLOOD PRESSURE; CARDIAC OUTPUT; FEMALE; HEART RATE; MALE; OXYGEN CONSUMPTION; PARTIAL PRESSURE; PLATELET AGGREGATION; PULMONARY ARTERY; PULMONARY CIRCULATION; SHOCK, SEPTIC; SULFONYLUREA COMPOUNDS; SWINE; THROMBOXANE A2;

ANIMALIA; SUS SCROFA;

EID: 9144221357     PISSN: 13813455     EISSN: None     Source Type: Journal    
DOI: 10.1076/apab.111.3.224.23457     Document Type: Article

References (28)

1. Altavilla D, Canale P, Squadrito F, Sardella A, Ammendolia L, Urna G, Ioculano M, Squadrito G, Caputi AP (1994): Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock. Pharmacol Res 30: 137-151.
2. Balk RA, Jacobs RF, Tryka AF, Townsend JW, Walls RC, Bone RC (1988): Effects of ibuprofen on neutrophil function and acute lung injury in canine endotoxin shock. Crit Care Med 16: 1121-1127.
3. Bernard GR, Reines HD, Halushka PV, Higgins SB, Metz CA, Swindell BB, Wright PE, Watts FL, Vrbanac JJ (1991): Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. Am Rev Resp Dis 144: 1095-1101.
4. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB (1997): The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336: 912-918.
5. Brimioulle S, Julien V, Gust R, Kozlowski JK, Naeije R, Schuster DP (2002): Importance of hypoxic vasoconstriction in maintaining oxygenation during acute lung injury. Crit Care Med 30: 874-880.
6. Deby-Dupont G, Braun M, Lamy M, Deby C, Pincemail J, Faymonville ME, Damas P, Bodson L, Lecart MP, Goutier R (1987): Thromboxane and prostacyclin release in adult respiratory distress syndrome. Intensive Care Med 13: 167-174.
7. Dogne JM, de Leval X, Neven P, Rolin S, Wauters J, David JL, Delarge J, Massereel B (2000): Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids 62: 311-317.
8. FitzGerald GA, Reilly IA, Pedersen AK (1985): The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 72: 1194-1201.
9. Fourie PR, Coetzee AR, Bolliger CT (1992): Pulmonary artery compliance: its role in right ventricular-arterial coupling. Cardiovasc Res 26: 839-844.
10. Grant BJB, Paradowski LJ (1987): Characterization of pulmonary arterial input impedance with lumped parameters models. Am J Physiol 252: H585-H593.
11. Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB (1991): Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit Care Med 19: 1339-1347.
12. Iglesias G, Zeigler ST, Lentz CW, Traber DL, Herndon DN (1994): Thromboxane synthetase inhibition and thromboxane receptor blockade preserve pulmonary and circulatory function in a porcine burn sepsis model. J Am Coll Surg 179: 187-192.
13. Jesmok G, Gundel R (1995): Thromboxane-blocked swine as an experimental model of severe intravascular inflammation and septic shock. Shock 4: 379-383.
14. Lambermont B, Gérard P, Kolh P, Detry O, Marcelle R, D'Orio V (1998): Time domain method to identify simultaneously parameters of the windkessel model applied to the pulmonary circulation. Arch Physiol Biochem 106: 245-252.
15. Lambermont B, Kolh P, Detry O, Gérard P, Marcelle R, D'Orio V (1999): Analysis of endotoxin effects on the intact pulmonary circulation. Cardiovasc Res 41: 275-281.
16. Mikashima H, Muramoto Y (1990): Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. Thromb Res 57: 499-505.
17. Ogletree ML, Brigham KL (1982): Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep. Prostaglandins Leukot Med 8: 489-502.
18. Redl G, Abdi S, Traber LD, Nichols RJ, Flynn JT, Herndon DN, Traber DL (1991): Inhibition of thromboxane synthesis reduces endotoxin-induced right ventricular failure in sheep. Crit Care Med 19: 1294-1302.
19. Rolin S, Dogne JM, Michaux C, Delarge J, Masereel B (2001): Activity of a novel dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids 65: 67-72.
20. Schuster DP, Kozlowski JK, Brimioulle S (2001): Effects of thromboxane receptor blockade on pulmonary capillary hypertension in acute lung injury. Am J Respir Crit Care Med 163: A820.
21. Spinas GA, Bloesch D, Keller U, Zimmerli W, Cammisuli S (1991): Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. J Infect Dis 163: 89-95.
22. Suchner U, Katz DP, Furst P, Beck K, Felbinger TW, Senftleben U, Thiel M, Goetz AE, Peter K (2001): Effects of intravenous fat emulsions on lung function in patients with acute respiratory distress syndrome or sepsis. Crit Care Med 29: 1569-1574.
23. Suchner U, Katz P, Furst P, Beck K, Felbinger W, Thiel M, Senftleben U, Goetz E, Peter K (2002): Impact of sepsis, lung injury, and the role of lipid infusion on circulating prostacyclin and thromboxane A2. Intensive Care Med 28: 122-129.
24. Tran HS, Quinn JV, Puc MM, Woolley DS, Puglisi RN, Slotman GJ (2001): Prostacyclin is neither sufficient alone nor necessary to cause pulmonary dysfunction: Results from infusions of prostacyclin and antiprostacyclin antibody in porcine septic shock. Crit Care Med 29: 1445-1451.
25. Uematsu T, Nagashima S, Inaba H, Mizuno A, Kosuge K, Nakashima M (1994): Pharmacokinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers. J Clin Pharmacol 34: 41-47.
26. VanWylen SJ, Browning DP, Villalba M (1986): The effect of imidazole in endotoxin shock in dogs. Am Surg 52: 413-417.
27. Wanecek M, Rudehill A, Hemsen A, Lundberg JM, Weitzberg E (1997): The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Crit Care Med 25: 848-857.
28. Wise WC, Cook JA, Halushka PV (1981): Implications for thromboxane A2 in the pathogenesis of endotoxic shock. Adv Shock Res 6: 83-91.